Antiretroviral therapy coverage in Mongolia
Mongolia: Antiretroviral therapy coverage was 41.0% in 2024. ◆ Volatile
Antiretroviral therapy coverage in Mongolia, 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of people living with HIV.
Analysis
The most recent figure for antiretroviral therapy coverage in Mongolia is 41.0%, measured in 2024. That is the highest value across all 25 years on record.
The figure is up 5.1% on the previous year and up 64.0% over ten years.
Over the whole period, antiretroviral therapy coverage in Mongolia peaked at 41.0% in 2024 and was at its lowest, 0.0%, in 2000.
Mongolia ranks 131st of 143 countries on this measure, in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage in Mongolia, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 1.0% | — |
| 2004 | 0.0% | -100.0% |
| 2005 | 0.0% | — |
| 2006 | 1.0% | — |
| 2007 | 1.0% | +0.0% |
| 2008 | 1.0% | +0.0% |
| 2009 | 3.0% | +200.0% |
| 2010 | 6.0% | +100.0% |
| 2011 | 9.0% | +50.0% |
| 2012 | 12.0% | +33.3% |
| 2013 | 20.0% | +66.7% |
| 2014 | 25.0% | +25.0% |
| 2015 | 28.0% | +12.0% |
| 2016 | 29.0% | +3.6% |
| 2017 | 33.0% | +13.8% |
| 2018 | 34.0% | +3.0% |
| 2019 | 33.0% | -2.9% |
| 2020 | 36.0% | +9.1% |
| 2021 | 38.0% | +5.6% |
| 2022 | 39.0% | +2.6% |
| 2023 | 39.0% | +0.0% |
| 2024 | 41.0% | +5.1% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.7% | 0.0% | 3.0% | 10 |
| 2010s | 22.9% | 6.0% | 34.0% | 10 |
| 2020s | 38.6% | 36.0% | 41.0% | 5 |
Countries ranked near Mongolia
- 129 Egypt 45.0% compare
- 130 Gambia 44.0% compare
- 131 Bangladesh 41.0% compare
- 131 Indonesia 41.0% compare
- 134 Philippines 40.0% compare
More health data for Mongolia
- Un projection of annual infant deaths, annual growth rate -1.56 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.6056 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 847.3 deaths per 1,000 people (2090)
- Number of infants who die before age 1 63 deaths (2100)
- Population ages 30-34, female, annual growth rate -4.44 % change on previous year (2025)
- Population ages 30-34, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 30-34, female, per capita 0.0353 units per person (2025)
- Population ages 30-34, male, annual growth rate -4.25 % change on previous year (2025)
- Population ages 30-34, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 30-34, male, per capita 0.037 units per person (2025)
Frequently asked questions
- What is antiretroviral therapy coverage in Mongolia?
- Antiretroviral therapy coverage in Mongolia was 41.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage recorded in Mongolia?
- The highest recorded value was 41.0% in 2024.
- What is the lowest antiretroviral therapy coverage recorded in Mongolia?
- The lowest recorded value was 0.0% in 2000.
- How does Mongolia rank for antiretroviral therapy coverage?
- Mongolia ranks 131st out of 143 countries with data for 2024.
- Is antiretroviral therapy coverage rising or falling in Mongolia?
- Over the last ten years it is up 64.0%. The long-run trend across the full record is volatile.
- Where does this Mongolia data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage (% of people living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.